Research Topics
Genomes and Genes
| Daniel R CarrascoSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesisDaniel R Carrasco
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, and Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
Cancer Cell 11:349-60. 2007..The similarities of this model with the human disease, coupled with documented frequent XBP-1s overexpression in human MM, serve to implicate XBP-1s dysregulation in MM pathogenesis...- Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implicationsTeru Hideshima
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 113:5228-36. 2009..Combination therapy targeting these kinases therefore represents a promising treatment strategy in MM... - A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaGullu Gorgun
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Blood 115:5202-13. 2010..MLN8237 is currently in phase 1 and phase 2 clinical trials in patients with advanced malignancies, and our preclinical results suggest that MLN8237 may be a promising novel targeted therapy in MM... 
BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cellsMala Mani
Department of Medical Oncology and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Cancer Res 69:7577-86. 2009..The pleiotropic roles of BCL9 reported in this study underscore its value as a drug target for therapeutic intervention in several malignancies associated with aberrant Wnt signaling...- Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironmentMasahisa Jinushi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Cancer Res 68:8889-98. 2008..Together, these findings delineate pleiotropic roles for MFG-E8 in the tumor microenvironment and raise the possibility that systemic MFG-E8 blockade might prove therapeutic for melanoma patients... - Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progressionJui Dutta-Simmons
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Blood 114:2699-708. 2009..Our data provide evidence for a novel functional link between beta-catenin and Aurora kinase A, underscoring a critical role of these pathways in MM disease progression... - Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myelomaKumar Sukhdeo
Department of Medical Oncology, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 104:7516-21. 2007..Taken together, these data demonstrate the efficacy of disrupting the beta-catenin/TCF transcriptional complex to exploit tumor dependence on Wnt signaling as a therapeutic approach in the treatment of MM... - A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cellsTeru Hideshima
Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 115:3772-5. 2010.... - CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cellsYu Tzu Tai
LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 113:4309-18. 2009..These studies provide direct evidence of the role of CS1 in myeloma pathogenesis, define molecular mechanisms regulating its effects, and further support novel therapies targeting CS1 in MM... - MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSFMasahisa Jinushi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Invest 117:1902-13. 2007..These findings clarify the immunoregulatory effects of apoptotic cells and suggest new therapeutic strategies to modulate CD4(+) T cell subsets in cancer and autoimmunity... 
Mouse models of human myelomaConstantine S Mitsiades
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Hematol Oncol Clin North Am 21:1051-69, viii. 2007..Here we review the recent developments in the generation of mouse models of MM and their impact as preclinical models for designing and assessing target-based therapeutic approaches...- Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouseChristine M Khoo
Department of Medical Oncology, Belfer Foundation Institute for Innovative Cancer Science, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 104:3931-6. 2007..These observations highlight the importance of genetic context in dictating whether telomere dysfunction promotes or suppresses age-related degenerative conditions as well as the rate of initiation and type of spontaneous cancers... - Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaYu Tzu Tai
LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
Blood 120:1877-87. 2012..Together, these results delineate functional sequelae of Btk activation mediating osteolysis and growth of MM cells, supporting evaluation of PCI-32765 as a novel therapeutic in MM... - FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasisJi Hye Paik
Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
Cell 128:309-23. 2007..Functional studies validated Sprouty2 and PBX1, among others, as FoxO-regulated mediators of endothelial cell morphogenesis and vascular homeostasis... - The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humansDaniel R Carrasco
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Cell 9:379-90. 2006..These genetic and translational observations establish a cooperative role of Pten and Ink4a/Arf in the development of HS and provide mechanistic insights into the pathogenesis of human HS... - Pathogenesis of myelomaKenneth C Anderson
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Annu Rev Pathol 6:249-74. 2011.... - Constitutive telomerase expression promotes mammary carcinomas in aging miceSteven E Artandi
Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street M413, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 99:8191-6. 2002..These data indicate that enforced mTERT expression can promote the development of spontaneous cancers even in the setting of ample telomere reserve... - High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patientsDaniel R Carrasco
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Cell 9:313-25. 2006.... - Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cellsTeru Hideshima
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 114:1046-52. 2009..Moreover, IKKbeta inhibitors enhanced bortezomib-induced cytotoxicity. Our studies therefore suggest that bortezomib-induced cytotoxicity cannot be fully attributed to inhibition of canonical NF-kappaB activity in MM cells... - PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activityVictor Pena-Cruz
Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
J Invest Dermatol 130:2222-30. 2010..Thus the PD-1 pathway is active in iLCs and inhibits iLC activities, but expression of receptor and ligands reverses upon maturation and PD-L1 and PD-L2 on mLC function to inhibit T-cell responses...
Research Grants
- Novel System to Study Telomere Dynamics in HemotopoiesisRuben Carrasco; Fiscal Year: 2005..He also holds a Ph.D. in Biochemistry. The research will be carried out in a cancer/aging biology laboratory within the Dana-Farber Cancer Institute, an affiliate of the Harvard Medical School, under the mentorship of Dr. Ron DePinho. ..
- Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeuticsRuben D Carrasco; Fiscal Year: 2010..The studies proposed in this RO1 are significant to Public Health in that they may lead to the development of novel pharmacologic strategies to treat MM and other cancers associated with deregulated Wnt signaling. ..